Myriad Genetics Inc MYGN

US Biotechnology

$2.86 ▼ -46.74% ($-2.51)

🧊 52W Low ⬇️ Below Yest. Low

Open $3.10

Prev Close $5.37

Day Range $2.81 – $3.26

52W Range $2.81 – $8.59

Market Cap $270.12M

Beta 1.65

EPS (TTM) $-1.20

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1995-10-06
Shares Out.	94,450,000
Website	myriad.com/ ↗
Phone	13026587581
Employees	2,700
Revenue	$200.4M
Gross Profit	$137.6M
Net Income	-$34.1M
Free Cash Flow	-$13.3M
Total Assets	$673.7M
Total Liabilities	$336.3M
Equity	$337.4M

About Myriad Genetics Inc

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Myriad Genetics Inc is a publicly traded company under the ticker symbol MYGN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.